Third Pole Therapeutics has announced a deal with Chiesi Farmaceutici giving Chiesi global rights to develop and commercialize Third Pole’s tankless inhaled nitric oxide (iNO) delivery system for the treatment of infants with hypoxic respiratory failure in neonatal intensive care. Third Pole had previously announced a strategic collaboration agreement with Johnson & Johnson subsidiary Actelion in March 2019.
In May 2017, Third Pole’s iNO technology won the Johnson & Johnson Innovation – JLABS @ M2D2 QuickFire Challenge. The company’s tankless, on-demand iNO delivery technology is protected by numerous patents.
Third Pole CEO Bill Athenson commented, “Chiesi’s essential, high quality products, and its sales and marketing team’s respected presence in nearly every neonatal intensive care unit will facilitate rapid early adoption of Third Pole’s device, a tankless platform that generates iNO in unlimited quantities by combining room air with electricity. The combination of tankless portable technology and Chiesi Group’s global reach could dramatically expand access to life-sustaining iNO and fulfill a very large and long-standing unmet worldwide need.”
Chiesi Group Global Strategy & Corporate Development Head Giovanna Amadori said, “This partnership is a concrete demonstration of Chiesi’s continuous commitment to embrace state-of-the-art technologies, with the aim of providing patients and their caregivers with innovative solutions to improve their quality of life. When approved, Third Pole will offer a truly tankless and reagent free solution for iNO delivery.”
Read the Third Pole Therapeutics press release.
